Cartesian Therapeutics SG&A Expense (TTM) Insights

Cartesian Therapeutics Inc (RNAC)

27.01 -1.51 (-5.29%) USD | NASDAQ | Jun 28, 16:00

26.60 -0.41 (-1.52%) After-Hours: 20:00

SG&A Expense (TTM) Chart

Historical SG&A Expense (TTM) Data

View and export this data back to 2015. Upgrade now.

Date	Value
March 31, 2024	44.34M
December 31, 2023	40.58M
September 30, 2023	24.74M
June 30, 2023	23.89M
March 31, 2023	24.02M
December 31, 2022	23.86M
September 30, 2022	23.08M
June 30, 2022	22.75M
March 31, 2022	21.27M
December 31, 2021	20.94M
September 30, 2021	20.16M
June 30, 2021	19.13M
March 31, 2021	20.02M
December 31, 2020	18.91M
September 30, 2020	18.23M
June 30, 2020	17.50M
March 31, 2020	15.97M

Date	Value
December 31, 2019	16.39M
September 30, 2019	17.46M
June 30, 2019	17.83M
March 31, 2019	18.08M
December 31, 2018	18.24M
September 30, 2018	18.76M
June 30, 2018	19.08M
March 31, 2018	19.62M
December 31, 2017	18.83M
September 30, 2017	18.91M
June 30, 2017	17.03M
March 31, 2017	14.54M
December 31, 2016	13.05M
September 30, 2016	9.324M
June 30, 2016	9.024M
March 31, 2016	8.844M
December 31, 2015	8.335M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (TTM) Range, Past 5 Years

15.97M

Minimum

Mar 2020

44.34M

Maximum

Mar 2024

22.80M

Average

20.94M

Median

Dec 2021

SG&A Expense (TTM) Benchmarks